Key Differences between Biosimilars and Generics
19 September 2025 Category: Clinical TrialGenerics and biosimilars both make drugs cheaper, but they behave very differently after a patent dies.
Generics and biosimilars both make drugs cheaper, but they behave very differently after a patent dies.
Here’s what that means: traditional anticoagulants—like warfarin and LMWHs—still form the backbone of hospital and community care
Artificial intelligence (AI) has become a transformative force in the increasingly digitized healthcare environment.
2025 is not just another year, a wave of innovation is crashing through biotech and bioinformatics, reshaping every stage of clinical development.
AI is no longer a distant vision in healthcare. It’s a $13.8 billion market today—and it's projected to soar past $164 billion by 2029. That’s over 1,000% growth in just a few years.